IL210269A - Crystalline forms of (s2, r3, r4, s5, r6) –2– (4 – chloro – 3 - (4-ethoxybenzyl) phenyl) –6 - (methyl theo) tetrahydro-h2 - pyran - 3, 4, 5 -Triol and the pharmaceutical compositions containing them - Google Patents

Crystalline forms of (s2, r3, r4, s5, r6) –2– (4 – chloro – 3 - (4-ethoxybenzyl) phenyl) –6 - (methyl theo) tetrahydro-h2 - pyran - 3, 4, 5 -Triol and the pharmaceutical compositions containing them

Info

Publication number
IL210269A
IL210269A IL210269A IL21026910A IL210269A IL 210269 A IL210269 A IL 210269A IL 210269 A IL210269 A IL 210269A IL 21026910 A IL21026910 A IL 21026910A IL 210269 A IL210269 A IL 210269A
Authority
IL
Israel
Prior art keywords
ethoxybenzyl
triol
pyran
methylthio
tetrahydro
Prior art date
Application number
IL210269A
Other languages
English (en)
Hebrew (he)
Other versions
IL210269A0 (en
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of IL210269A0 publication Critical patent/IL210269A0/en
Publication of IL210269A publication Critical patent/IL210269A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL210269A 2008-07-17 2010-12-26 Crystalline forms of (s2, r3, r4, s5, r6) –2– (4 – chloro – 3 - (4-ethoxybenzyl) phenyl) –6 - (methyl theo) tetrahydro-h2 - pyran - 3, 4, 5 -Triol and the pharmaceutical compositions containing them IL210269A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17
PCT/US2009/050636 WO2010009197A1 (en) 2008-07-17 2009-07-15 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use

Publications (2)

Publication Number Publication Date
IL210269A0 IL210269A0 (en) 2011-03-31
IL210269A true IL210269A (en) 2015-06-30

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210269A IL210269A (en) 2008-07-17 2010-12-26 Crystalline forms of (s2, r3, r4, s5, r6) –2– (4 – chloro – 3 - (4-ethoxybenzyl) phenyl) –6 - (methyl theo) tetrahydro-h2 - pyran - 3, 4, 5 -Triol and the pharmaceutical compositions containing them

Country Status (28)

Country Link
US (2) US8217156B2 (enExample)
EP (1) EP2332947B1 (enExample)
JP (2) JP2011528366A (enExample)
KR (2) KR20170010069A (enExample)
CN (2) CN107629097A (enExample)
AR (1) AR072807A1 (enExample)
AU (1) AU2009270973B2 (enExample)
CA (1) CA2730931A1 (enExample)
CL (1) CL2009001595A1 (enExample)
CO (1) CO6351797A2 (enExample)
DK (1) DK2332947T3 (enExample)
ES (1) ES2656357T3 (enExample)
HK (1) HK1243713A1 (enExample)
HU (1) HUE035400T2 (enExample)
IL (1) IL210269A (enExample)
MX (1) MX2011000503A (enExample)
NO (1) NO2332947T3 (enExample)
NZ (1) NZ590184A (enExample)
PE (1) PE20100260A1 (enExample)
PL (1) PL2332947T3 (enExample)
PT (1) PT2332947T (enExample)
RU (1) RU2505543C2 (enExample)
SG (1) SG185317A1 (enExample)
TW (1) TWI472521B (enExample)
UA (1) UA106048C2 (enExample)
UY (1) UY31992A (enExample)
WO (1) WO2010009197A1 (enExample)
ZA (1) ZA201100175B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
EP2183263B1 (en) 2007-07-26 2011-10-26 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA117574C2 (uk) * 2012-11-20 2018-08-27 Лексікон Фармасьютікалз, Інк. Інгібітори котранспортера натрій-глюкози 1
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
CN108026133B (zh) 2015-07-30 2021-05-07 公益财团法人微生物化学研究会 有效对抗多药耐药细菌的新的氨基糖苷抗生素
WO2017202351A1 (zh) * 2016-05-25 2017-11-30 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR20210065974A (ko) * 2018-09-26 2021-06-04 렉시컨 파마슈티컬스 인코퍼레이티드 N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
CN112955214B (zh) 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955215B (zh) 2018-10-29 2024-05-17 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
CN113993865B (zh) * 2019-07-05 2023-09-22 山东丹红制药有限公司 一种SGLTs抑制剂的晶型及其应用
EP3771718A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
WO2022144465A1 (en) 2021-01-04 2022-07-07 Charité-Universitätsmedizin Berlin Sotagliflozin for improving left atrial function
US20220370485A1 (en) 2021-01-14 2022-11-24 Lexicon Pharmaceuticals, Inc. Compounds and methods for treating or preventing cardiovascular diseases and conditions
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
US20250108032A1 (en) 2023-09-28 2025-04-03 Lexicon Pharmaceuticals, Inc. Methods of treating type 1 diabetes and kidney disease
US20250114323A1 (en) 2023-10-06 2025-04-10 Lexicon Pharmaceuticals, Inc. Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy
PL446852A1 (pl) * 2023-11-27 2025-06-02 Politechnika Rzeszowska im. Ignacego Łukasiewicza Układ doprowadzający wodę do pralki

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
EP2183263B1 (en) * 2007-07-26 2011-10-26 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
IL210269A0 (en) 2011-03-31
UY31992A (es) 2010-02-26
KR101707246B1 (ko) 2017-02-15
US8217156B2 (en) 2012-07-10
RU2505543C2 (ru) 2014-01-27
RU2011105797A (ru) 2012-08-27
US20130165395A1 (en) 2013-06-27
JP6283337B2 (ja) 2018-02-21
AU2009270973A1 (en) 2010-01-21
ZA201100175B (en) 2012-03-28
MX2011000503A (es) 2011-03-01
HUE035400T2 (en) 2018-05-02
CO6351797A2 (es) 2011-12-20
TW201006808A (en) 2010-02-16
BRPI0916191A2 (pt) 2017-08-29
EP2332947A1 (en) 2011-06-15
CL2009001595A1 (es) 2010-07-19
TWI472521B (zh) 2015-02-11
JP2016041701A (ja) 2016-03-31
HK1243713A1 (zh) 2018-07-20
UA106048C2 (uk) 2014-07-25
NO2332947T3 (enExample) 2018-03-31
PE20100260A1 (es) 2010-04-16
KR20110031196A (ko) 2011-03-24
SG185317A1 (en) 2012-11-29
DK2332947T3 (da) 2018-01-29
KR20170010069A (ko) 2017-01-25
CN102112483A (zh) 2011-06-29
CA2730931A1 (en) 2010-01-21
AU2009270973B2 (en) 2014-01-30
AR072807A1 (es) 2010-09-22
ES2656357T3 (es) 2018-02-26
PT2332947T (pt) 2018-02-06
JP2011528366A (ja) 2011-11-17
CN107629097A (zh) 2018-01-26
EP2332947B1 (en) 2017-11-01
US20100016422A1 (en) 2010-01-21
WO2010009197A1 (en) 2010-01-21
US9067962B2 (en) 2015-06-30
PL2332947T3 (pl) 2018-04-30
NZ590184A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
IL210269A (en) Crystalline forms of (s2, r3, r4, s5, r6) –2– (4 – chloro – 3 - (4-ethoxybenzyl) phenyl) –6 - (methyl theo) tetrahydro-h2 - pyran - 3, 4, 5 -Triol and the pharmaceutical compositions containing them
PL2661256T3 (pl) Kompozycje zawierające (2S,3R,4R,5S,6R)-2-(4-chloro-3)-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triol
HUE035947T2 (hu) A (2S,3R,4R,5S,6R)-2-(4-klór-3-benzilfenil)-6-(hidroximetil)tetrahidro-2H-pirán-3,4,5-triol származékainak felhasználása a diabétesz kezelésében
PL2707366T3 (pl) Ko-kryształy (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorofenylo)tiofen-2-ylo)metylo)-4-metylofenylo)-6-(hydroksymetylo)tetrahydro-2H-pirano-3,4,5-triolu z L-proliną i z kwasem cytrynowym
IL216492A (en) Crystalline Forms of (s) - Isopropyl 2 - ((s - ((2r, 3r, 4r, 5r) –5– (4.2– Dioxo – 4,3 – Dihydropyrimidine – 1 (H2) - Yl) –4 – Fluoro -3-Hydroxy-4-Methyltetrahydrofuran-2-Yl) -Methoxy) - (Phenoxy) Phosphorylamino) Propanoate, Pharmaceutical Preparations
IL204145A (en) Processes for the preparation of sglt inhibitors, crystalline forms of 1– (d – β ––– glucopyranosyl) –4 – chloro – 3– [5– (6-fluoro-3-pyridyl) –2-thienylmethyl] benzene, pharmaceutical preparations containing them and uses In them
IL197836A (en) Florizine analogues and pharmaceuticals containing them
SI1901734T1 (sl) Sestavki, ki obsegajo kristaliničen trans-(+/-) -delta-9-tetrahidrokanabinol
ZA200801945B (en) Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
IL186808A0 (en) Topiramate compositions for treatment of headache
WO2007125103A3 (en) Benzamide glucokinase activators
IL225672B (en) Pharmaceutical composition comprising (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol for inhibiting rna viral polymerase
IL187999A0 (en) Compositions for the treatment of persistent infections
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
IL199181A (en) The crystalline form of a monosulfate salt of 2– chloro – 4– [1– (4 – fluoro – phenyl) –2,5 – dimethyl– h1– imidazole – 4 – ylethinyl] –pyridine, its pharmaceutical preparations and uses
ZA200800771B (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin deseases
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
IL205510A0 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose - 1, 6 - bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
PL1951879T3 (pl) Rośliny o podwyższonej zawartości aminocukrów
WO2012173410A3 (en) Novel c-aryl ansa sglt2 inhibitors
TH122363A (th) รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้
EP1833491A4 (en) TOPICAL COMPOSITIONS WITH ONE OR MORE 44-THIURIDINE, ISOMALTITOL AND URIDINE
ZA200703308B (en) Improvements to high speed uplink packet access scheme
PL380678A1 (pl) Kompozycja soku, nektaru lub napoju i jej zastosowanie

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed